Baird analyst Rob Oliver downgrades UserTesting (NYSE:USER) from Outperform to Neutral.
Why Is Small-Cap Metabolic-Focused Rezolute Stock Trading Higher On Wednesday?
Rezolute announced topline results from the Phase 2 study of RZ402 for diabetic macular edema, showing significant improvements in macular edema and a favorable safety profile.